Publications

European urology oncology

Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.

01-04-2026

European urology oncology

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis.

01-04-2026

Annals of oncology : official journal of the European Society for Medical Oncology

Repertoire and clinical hierarchy of AR locus alterations in castration-resistant prostate cancer.

01-03-2026

NAR genomics and bioinformatics

DEprot: a comprehensive R-package for the analysis of label-free quantitation mass spectrometry data.

01-03-2026

Therapeutic drug monitoring

Impact of Abiraterone Therapeutic Drug Monitoring on Cortisol as a Surrogate Biomarker of CYP17 Inhibition in Metastatic Prostate Cancer Treatment.

13-02-2026

European urology oncology

Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.

01-08-2025

Cell reports. Medicine

Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer.

15-07-2025

Communications biology

TRIM33 loss reduces androgen receptor transcriptional output and H2BK120 ubiquitination.

11-07-2025

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with ²²³Ra Therapy in Daily Practice.

01-07-2025

Clinical genitourinary cancer

Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

01-06-2025

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.

10-05-2025

British journal of cancer

Feasibility and efficacy of therapeutic drug monitoring of abiraterone in metastatic castration resistant prostate cancer patients.

01-04-2025

Genome medicine

Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications.

20-03-2025

Cancer discovery

Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.

03-03-2025

The Journal of clinical investigation

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

19-11-2024

bioRxiv

Human Prostate Cancer-Associated Macrophage Subtypes and Prognostic Potential Revealed by Single-cell Transcriptomics

20-06-2020

Key